Latest Commercial Revenue News

Jade Gas Holdings has raised A$5 million through a placement to advance commercial gas production at its Red Lake field, with a follow-up Share Purchase Plan aiming to raise an additional A$2.1 million.

Skin Elements Limited has locked in $2.5 million through a two-tranche placement to accelerate the commercial rollout of its SE Formula biotechnology products, offering investors discounted shares and options.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Centuria Capital Group reported a robust FY25 with $19.7 billion in assets under management and earnings per stapled security exceeding guidance. The group is poised for strong FY26 growth, driven by stabilizing real estate markets and its pioneering sovereign AI Factory.

Cleo Diagnostics has launched a health economic study in partnership with EntityRisk and Norstella to support the U.S. market entry of its Ovarian Cancer Pre-Surgical Test, aiming to refine reimbursement strategies and accelerate commercialisation.

Temple & Webster Group Ltd has reported record FY25 results with revenue climbing 20.7% to $600.7 million and profit before tax more than doubling to $14.8 million, driven by market share gains and disciplined cost management.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 45 active trials worldwide and anticipates UK revenue by Q2 FY26 following successful supermarket partnerships.

Artrya has launched its AI-powered Salix Coronary Anatomy platform in the U.S. and submitted its Coronary Plaque module for FDA clearance, marking a key step in its commercial expansion. A new five-year contract with Tanner Health signals the start of U.S. revenues.